Replies to post #83 on Clearside BioMedical Inc (CLSD)

[kei]

great post and i appreciate it - i assume you are bullish after taking all those skeptical points you indicated - as i posted here, it is obvious that the company is using ATM - do you know how much do they still have left?
in my opinion, if the company needs raise cash, they just do simple stock offering not ATM.

[finesand]

Napkin Valuation for XIPERE for Uveitis

US Market Size 210k eyes or $466M in 2020 (slides)

We expect the same additional market size of the EU and then probably China - but it would be fair to say double market size world wide!

Let's use conservative multiples now:

$460M US market size -> $23M revenue @ 10% market penetration
$23M gross profits or EBITDA @ 50% margin
$18.4M MCAP or $0.575/sh P/E 1 @ 20% discount late stage phase

P/E 15 is conservative, which we will use here.

P/E 15: $276M MCAP or $8.62/sh for the US only.

Current PT of $5+ can be reached by using P/E around 10, while excluding ex-US licensing income.

Company is not a one drug wonder play, but has several other in their pipeline - do your DD.

Nice SP plunge! Thank you markets.
Reiterating the rational behind the $5+ valuation
based on Xipere US alone w/o SPC.

Also check the magic $0.57 SP P/E 1 on Xipere US alone.

GL